Significance of CD47 expression in gastric cancer

Sudo,Tomoya; Takahashi,Yusuke; Sawada,Genta; Uchi,Ryutaro; Mimori,Koshi; Akagi,Yoshito

doi:10.3892/ol.2017.6257

Significance of CD47 expression in gastric cancer

Authors:
- Tomoya Sudo
- Yusuke Takahashi
- Genta Sawada
- Ryutaro Uchi
- Koshi Mimori
- Yoshito Akagi
View Affiliations

Affiliations: Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan, Department of Surgical Oncology, Osaka University, Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita 847‑0838, Japan
Published online on: May 26, 2017 https://doi.org/10.3892/ol.2017.6257
Pages: 801-809
Copyright: © Sudo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Integrin-associated protein (CD47) is ubiquitously expressed on the surface of cells and functions as an identifier of self. In blood cancer, tumor cells expressing CD47 evade phagocytosis by macrophages, leading to a poor patient prognosis. However, the status of CD47 expression in solid tumors, particularly in gastric cancer, is not well understood. The purpose of the present study was to examine the level of CD47 in the primary tumor, peripheral blood (PB) and bone marrow (BM) of patients with gastric cancer, and to determine its effect. Reverse transcription-quantitative polymerase chain reaction analysis was performed to determine the level of CD47 mRNA expression in primary tumor, PB and BM samples collected from 168 patients with gastric cancer. Cell sorting was performed to investigate CD47 protein expression in PB and BM fractions, and to identify the source of CD47 expression. In primary tumors, the expression of CD47 was not associated with any clinicopathological factors or prognosis. By contrast, in PB, the low CD47 expression group demonstrated a significantly increased tumor size, and frequency of lymphatic invasion and lymph node metastasis, compared with the high CD47 expression group. In addition, the clinical tumor stage of the low CD47 expression group was significantly increased compared with that of the high CD47 expression group. Conversely, in PB, the high CD47 expression group had a significantly higher frequency of lymphatic invasion and lymph node metastasis compared with the low CD47 expression group. The lymphocyte fraction exhibited the highest CD47 expression compared with the other fractions in PB and BM samples. Low expression of CD47 was associated with the advancement of gastric cancer, in contrast to other cancers, and it may be associated with a decrease in lymphocytes during later stages. These results indicate that CD47 expression in the PB and BM may serve as a marker to analyze the immunological function of patients with gastric cancer; however, the significance of CD47 in gastric cancer requires further study.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 45:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
3	Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H and Sobue T: Research group of population-based cancer registries of Japan: Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: A chronological and international comparative study. Jpn J Clin Oncol. 41:40–51. 2011. View Article : Google Scholar : PubMed/NCBI
4	Mawby WJ, Holmes CH, Anstee DJ, Spring FA and Tanner MJ: Isolation and characterization of CD47 glycoprotein: A multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J. 304:525–530. 1994. View Article : Google Scholar : PubMed/NCBI
5	Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG and Brown EJ: In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J cell Sci. 108:3419–3425. 1995.PubMed/NCBI
6	Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD and Lindberg FP: Role of CD47 as a marker of self on red blood cells. Science. 288:2051–2054. 2000. View Article : Google Scholar : PubMed/NCBI
7	Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N and Weissman IL: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138:271–285. 2009. View Article : Google Scholar : PubMed/NCBI
8	Chao MP, Weissman IL and Majeti R: The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 24:225–232. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, et al: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA. 106:pp. 14016–14021. 2009; View Article : Google Scholar : PubMed/NCBI
10	Nagahara M, Mimori K, Kataoka A, Ishii H, Tanaka F, Nakagawa T, Sato T, Ono S, Sugihara K and Mori M: Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res. 16:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX and Xu MM: CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 21:1209–1215. 2015. View Article : Google Scholar : PubMed/NCBI
12	Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS and Roberts DD: Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets. 17:89–103. 2013. View Article : Google Scholar : PubMed/NCBI
13	Japanese Gastric Cancer Association, . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 20:1–19. 2017. View Article : Google Scholar
14	Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Bio Techniques. 15:532–534, 536-537. 1993.
15	Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, Ueo H and Akiyoshi T: The expression of tumor-rejection antigen ‘MAGE’ genes in human gastric carcinoma. Gastroenterology. 109:1522–1525. 1995. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N and Weissman IL: CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138:286–299. 2009. View Article : Google Scholar : PubMed/NCBI
18	Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL and Majeti R: Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71:1374–1384. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hoffmann W: Regeneration of the gastric mucosa and its glands from stem cells. Curr Med Chem. 15:3133–3144. 2008. View Article : Google Scholar : PubMed/NCBI
20	Hoffmann W: Stem cells, self-renewal and cancer of the gastric epithelium. Curr Med Chem. 19:5975–5983. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lee ER and Leblond CP: Dynamic histology of the antral epithelium in the mouse stomach: II. Ultrastructure and renewal of isthmal cells. Am J Anat. 172:205–224. 1985. View Article : Google Scholar : PubMed/NCBI
22	Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H and Nagata M: High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 13:170–176. 2010. View Article : Google Scholar : PubMed/NCBI
23	Balta S, Unlu M, Arslan Z and Demırkol S: Neutrophil-to- lymphocyte ratio in prognosis of gastric cancer. J Gastric Cancer. 13:196–197. 2013. View Article : Google Scholar : PubMed/NCBI
24	Cho IR, Park JC, Park CH, Jo JH, Lee HJ, Kim S, Shim CN, Lee H, Shin SK, Lee SK and Lee YC: Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer. Gastric Cancer. 17:703–710. 2014. View Article : Google Scholar : PubMed/NCBI
25	Petrillo A, Laterza MM, Ventriglia J, Savastano B, Tirino G, Pompella L, Martinelli E, Morgillo F, Orditura M, Ciardiello F and De Vita F: Prognostic implications of baseline neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in metastatic gastric cancer (GC) patients. Ann Oncol. 27:(Suppl 6): 652P2016. View Article : Google Scholar
26	Zhang X, Zhang W and Feng LJ: Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: A meta-analysis. PLoS One. 9:e1119062014. View Article : Google Scholar : PubMed/NCBI
27	Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH and Kim HJ: Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 13:3502013. View Article : Google Scholar : PubMed/NCBI
28	Hirashima M, Higuchi S, Sakamoto K, Nishiyama T and Okada H: The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol. 124:329–334. 1998. View Article : Google Scholar : PubMed/NCBI
29	Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y and Fukushima M: The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 73:215–220. 2007. View Article : Google Scholar : PubMed/NCBI
30	Saito H, Takaya S, Osaki T and Ikeguchi M: Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients. Gastric Cancer. 16:473–479. 2013. View Article : Google Scholar : PubMed/NCBI
31	Yoshida K, Tsujimoto H, Matsumura K, Kinoshita M, Takahata R, Matsumoto Y, Hiraki S, Ono S, Seki S, Yamamoto J and Hase K: CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer. Cancer Med. 4:1322–1333. 2015. View Article : Google Scholar : PubMed/NCBI